Aaron U Blackham1, Scott A Northrup1, Mark Willingham2, Joseph Sirintrapun2, Greg B Russell3, Douglas S Lyles4, John H Stewart5. 1. Division of Surgical Sciences, Department of General Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina. 2. Department of Pathology, Wake Forest School of Medicine, Winston-Salem, North Carolina. 3. Division of Public Health Sciences, Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, North Carolina. 4. Department of Biochemistry, Wake Forest School of Medicine, Winston-Salem, North Carolina. 5. Division of Surgical Sciences, Department of General Surgery, Wake Forest School of Medicine, Winston-Salem, North Carolina. Electronic address: jhstewar@wfubmc.edu.
Abstract
BACKGROUND: M protein mutant vesicular stomatitis virus (M51R-VSV) has oncolytic properties against many cancers. However, some cancer cells are resistant to M51R-VSV. Herein, we evaluate the molecular determinants of vesicular stomatitis virus (VSV) resistance in pancreatic adenocarcinoma cells. METHODS: Cell viability and the effect of β-interferon (IFN) were analyzed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Gene expression was evaluated via microarray analysis. Cell infectability was measured by flow cytometry. Xenografts were established in athymic nude mice and treated with intratumoral M51R-VSV. RESULTS: Four of five pancreatic cancer cell lines were sensitive to M51R-VSV, whereas Panc 03.27 cells remained resistant (81 ± 3% viability 72 h after single-cycle infection). Comparing sensitive MiaPaCa2 cells with resistant Panc 03.27 cells, significant differences in gene expression were found relating to IFN signaling (P = 2 × 10(-5)), viral entry (P = 3 × 10(-4)), and endocytosis (P = 7 × 10(-4)). MiaPaCa2 cells permitted high levels of VSV infection, whereas Panc 03.27 cells were capable of resisting VSV cell entry even at high multiplicities of infection. Extrinsic β-IFN overcame apparent defects in IFN-mediated pathways in MiaPaCa2 cells conferring VSV resistance. In contrast, β-IFN decreased cell viability in Panc 3.27 cells, suggesting intact antiviral mechanisms. VSV-treated xenografts exhibited reduced tumor growth relative to controls in both MiaPaCa2 (1423 ± 345% versus 164 ± 136%; P < 0.001) and Panc 3.27 (979 ± 153% versus 50 ± 56%; P = 0.002) tumors. Significant lymphocytic infiltration was seen in M51R-VSV-treated Panc 03.27 xenografts. CONCLUSIONS: Inhibition of VSV endocytosis and intact IFN-mediated defenses are responsible for M51R-VSV resistance in pancreatic adenocarcinoma cells. M51R-VSV treatment appears to induce antitumor cellular immunity in vivo, which may expand its clinical efficacy.
BACKGROUND: M protein mutant vesicular stomatitis virus (M51R-VSV) has oncolytic properties against many cancers. However, some cancer cells are resistant to M51R-VSV. Herein, we evaluate the molecular determinants of vesicular stomatitis virus (VSV) resistance in pancreatic adenocarcinoma cells. METHODS: Cell viability and the effect of β-interferon (IFN) were analyzed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium assay. Gene expression was evaluated via microarray analysis. Cell infectability was measured by flow cytometry. Xenografts were established in athymic nude mice and treated with intratumoral M51R-VSV. RESULTS: Four of five pancreatic cancer cell lines were sensitive to M51R-VSV, whereas Panc 03.27 cells remained resistant (81 ± 3% viability 72 h after single-cycle infection). Comparing sensitive MiaPaCa2 cells with resistant Panc 03.27 cells, significant differences in gene expression were found relating to IFN signaling (P = 2 × 10(-5)), viral entry (P = 3 × 10(-4)), and endocytosis (P = 7 × 10(-4)). MiaPaCa2 cells permitted high levels of VSV infection, whereas Panc 03.27 cells were capable of resisting VSV cell entry even at high multiplicities of infection. Extrinsic β-IFN overcame apparent defects in IFN-mediated pathways in MiaPaCa2 cells conferring VSV resistance. In contrast, β-IFN decreased cell viability in Panc 3.27 cells, suggesting intact antiviral mechanisms. VSV-treated xenografts exhibited reduced tumor growth relative to controls in both MiaPaCa2 (1423 ± 345% versus 164 ± 136%; P < 0.001) and Panc 3.27 (979 ± 153% versus 50 ± 56%; P = 0.002) tumors. Significant lymphocytic infiltration was seen in M51R-VSV-treated Panc 03.27 xenografts. CONCLUSIONS: Inhibition of VSV endocytosis and intact IFN-mediated defenses are responsible for M51R-VSV resistance in pancreatic adenocarcinoma cells. M51R-VSV treatment appears to induce antitumor cellular immunity in vivo, which may expand its clinical efficacy.
Authors: Sabrina Marozin; Jennifer Altomonte; Florian Stadler; Wolfgang E Thasler; Roland M Schmid; Oliver Ebert Journal: Mol Ther Date: 2008-09-09 Impact factor: 11.454
Authors: Eugene A Choi; Hanqin Lei; David J Maron; James M Wilson; James Barsoum; Douglas L Fraker; Wafik S El-Deiry; Francis R Spitz Journal: Cancer Res Date: 2003-09-01 Impact factor: 12.701
Authors: Timothy P Cripe; Minhtran C Ngo; James I Geller; Chrystal U Louis; Mark A Currier; John M Racadio; Alexander J Towbin; Cliona M Rooney; Adina Pelusio; Anne Moon; Tae-Ho Hwang; James M Burke; John C Bell; David H Kirn; Caroline J Breitbach Journal: Mol Ther Date: 2014-12-22 Impact factor: 11.454
Authors: Lukkana Suksanpaisan; Rong Xu; Mulu Z Tesfay; Carolyn Bomidi; Stefan Hamm; Rianna Vandergaast; Nathan Jenks; Michael B Steele; Ayuko Ota-Setlik; Hinna Akhtar; Amara Luckay; Rebecca Nowak; Kah Whye Peng; John H Eldridge; David K Clarke; Stephen J Russell; Rosa Maria Diaz Journal: Mol Ther Oncolytics Date: 2018-07-05 Impact factor: 7.200
Authors: Carles Urbiola; Frédéric R Santer; Monika Petersson; Gabri van der Pluijm; Wolfgang Horninger; Patrik Erlmann; Guido Wollmann; Janine Kimpel; Zoran Culig; Dorothee von Laer Journal: Int J Cancer Date: 2018-07-03 Impact factor: 7.396